MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study
Yang Cao, Wenxuan Huo, Jiayu Huang, Yang Yang, Yu Wang, Ying‐Jun Chang, Luxiang Wang, Zilu Zhang, Chuanhe Jiang, Xiaoxia Hu, Xiao‐Dong Mo
Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous disease distinguished by different cytogenetic and genetic characteristics [ 1 , 2 ]. Currently, the risk classification based on the cytogenetics and molecular markers (e.g., the European LeukemiaNet [ELN] risk stratification) is the mainstay criterion that direct the treatments of adult AML patients, and those with adverse-risk AML are recommended to receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) in their first complete remission (CR1) [ 1 , 3 ]. Several studies have reported that the efficacy of allo-HSCT is superior to that of those receiving consolidation chemotherapy alone in adverse-risk AML patients and the benefit of allo-HSCT is observed across ages and donor type [ 4 ].